NOVEN
TO PRESENT AT UBS GLOBAL GENERIC AND |
BackMiami, FL, May 3,
2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that Robert C. Strauss, its President, CEO & Chairman, is scheduled
to provide an update on Noven’s business and prospects at the
UBS Global Generic and Specialty Pharmaceuticals Conference in New
York City on Wednesday, May 9, 2007, at 9:30 a.m. Eastern Time. The
public is invited to listen to the presentation live via webcast at
www.noven.com, and a replay will be available for at least two weeks
at the same site.
Noven Pharmaceuticals, Inc., headquartered in Miami,
Florida, is a leading developer of advanced transdermal drug delivery
technologies and prescription transdermal products. Noven’s prescription
patches are approved in over 30 countries and include Vivelle-Dot® (the
most prescribed estrogen patch in the U.S.) and Daytrana™ (the
first and only patch approved for the treatment of ADHD). Noven is
committed to expanding the universe of available transdermal therapies
for the benefit of patients, partners and shareholders. See www.noven.com
for additional information.
Contact: |
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.